10% Owner Converts $28M in Preferred Stock to Common, Significantly Diluting Shares

summarizeSummary

Ampersand 2018 Limited Partnership, a 10% owner, converted $28 million worth of Series C Convertible Preferred Stock into 13.86 million common shares, representing a substantial change to the company's capital structure.

check_boxKey Events

• Major Preferred Stock Conversion

  Ampersand 2018 Limited Partnership converted $28 million of Series C Convertible Preferred Stock into 13,861,386 shares of common stock.

• Significant Dilution

  The conversion dramatically increases the number of common shares outstanding, representing a substantial dilution to existing common shareholders.

• Conversion Price Above Market

  The conversion occurred at an effective price of $2.02 per common share, which is above the current market price of $1.70.

• Follows Capital Structure Changes

  This transaction aligns with the 'significant capital structure changes' mentioned in the company's 8-K filing on the same date, January 20, 2026.

auto_awesomeAnalysis

This Form 4 details a massive conversion of preferred stock by a 10% owner, Ampersand 2018 Limited Partnership, into common equity. The conversion of $28 million in Series C Convertible Preferred Stock into 13.86 million common shares on January 20, 2026, represents an extremely significant event for Interpace Biosciences, Inc., given its current market capitalization. This transaction, occurring at a conversion price of $2.02 per share (above the current stock price of $1.70), substantially increases the outstanding common share count and is highly dilutive to existing common shareholders. It follows the company's 8-K filing on the same date, which alluded to significant capital structure changes. Investors should monitor the impact of this dilution on per-share metrics and the company's overall valuation.